🇺🇸 FDA
Patent

US 8003619

Method of stimulating an immune response and inhibiting expression of a gene using an oligonucleotide

granted A61KA61K2039/53A61K39/00

Quick answer

US patent 8003619 (Method of stimulating an immune response and inhibiting expression of a gene using an oligonucleotide) held by Alnylam Pharmaceuticals, Inc. expires Mon Aug 18 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Aug 23 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 18 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K2039/53, A61K39/00, A61K39/39, A61P